Starlynn Clarke, Ph.D.

Director of Preclinical Biology at Rondo Therapeutics

Speaker

Starlynn Clarke leads the preclinical biology group at Rondo Therapeutics, an IO-focused biopharmaceutical company developing innovative bispecific therapeutic antibodies for treating solid tumors. Starlynn has worked in discovery and preclinical development in the fields of oncology and immunology at several biotechnology start-up companies, including Frontier Medicines and Caribou Biosciences. As a founding member of the preclinical biology team at Teneobio, a highly successful multispecific therapeutic antibody company, she contributed to several bispecific antibody programs currently in clinical trials. Starlynn completed her PhD in the lab of Charles Craik at UCSF, where she studied novel viral and fungal host-pathogen interactions.